Dechra Pharmaceuticals PLC Dechra complete acquisition in Australia (5657M)
October 14 2016 - 3:01AM
UK Regulatory
TIDMDPH
RNS Number : 5657M
Dechra Pharmaceuticals PLC
14 October 2016
Friday, 14 October 2016
Dechra(R) Pharmaceuticals PLC
(Dechra, Company or the Group)
Dechra complete acquisition in Australia
Further to the announcement on 16 September 2016, Dechra is
pleased to announce that the acquisition of the business and assets
of Apex Laboratories Pty Ltd has now completed.
Enquiries to:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer
Office: +44 (0) 1606 814 730
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications Ltd
Fiona Tooley, Director
Mobile: +44 (0) 7785 703 523
e-mail: fiona@tooleystreet.com
About Dechra
Stock Code: Full Listing (Pharmaceuticals): DPH
Dechra is an international specialist veterinary pharmaceuticals
and related products business. Its expertise is in the development,
manufacture and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.
The Group's Preliminary results for the year ended 30 June 2016
were released on 5 September 2016. For more information, please
visit: www.dechra.com.
About Apex
Apex, based in Somersby near Sydney, Australia is a
pharmaceutical company which manufactures, markets and sells
branded non-proprietary prescription and other related companion
animal products in Australia and New Zealand. It will give Dechra
direct access to the established and growing Australian companion
animal product market and will provide a base from which to support
and build Dechra's expansion in the Australasian and Asian
regions.
Trademarks
Dechra and the Dechra 'D' logo are registered Trademarks of
Dechra Pharmaceuticals PLC.
Market Abuse Regulation (MAR)
The information contained within this announcement may
constitute inside information stipulated under the Market Abuse
Regulation (EU) No. 596/2014. Upon the publication of this
announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQGRBDGCUBBGLS
(END) Dow Jones Newswires
October 14, 2016 04:01 ET (08:01 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024